Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lyn Austen
Institutions:
Canberra Hospital,
Canterbury Health Laboratories
Observed institutions:
Princess Margaret Cancer Centre,
Canberra Hospital,
Canterbury Health Laboratories
OpenAlex ID:
A5086575366
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
2019
·
Sylvie Bonvalot
, Piotr L Rutkowski
, et al.
·
The Lancet Oncology
·
617
PDF
Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion
2005
·
Daniel Taussky
, Lyn Austen
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
105
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma
2022
·
Sylvie Bonvalot
, Piotr L. Rutkowski
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
52
PDF
Optimising the management of soft tissue tumours
2011
·
Chris Hemmings
, Carina Miles
, et al.
·
Pathology
·
2
PDF
Show more works
View as search
Works count:
4
Citation count:
775
H-index:
3
I10-index:
3
Year
Topic
Type